Off-label use of recombinant activated factor VII increases risk of arterial events
Off-label use of recombinant activated factor VII (rFVIIa) increases the risk of arterial but not venous thromboembolic events, particularly in…
RECENT POSTS
- Caring for diverse patient populations in their homes June 29, 2022
- Magnet® and COVID-19 response June 26, 2022
- Operationalizing the Pathway to Excellence® quality standard June 26, 2022
- ANA Statement on overturn of Roe vs. Wade June 24, 2022
- Do Vitamins, Plants Help Uterine Fibroid Risk or Treatment? June 23, 2022